Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 38Melanoma 15Neoplasm Metastasis 12Squamous Cell Carcinoma of Head and Neck 11Lung Neoplasms 11Skin Neoplasms 10Neoplasms 9Ovarian Neoplasms 8Recurrence 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Urinary Bladder Neoplasms 6Head and Neck Neoplasms 6Carcinoma, Basal Cell 6Breast Neoplasms 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Colonic Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma, Merkel Cell 5Carcinoma 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Mouth Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4Stomach Neoplasms 3Sarcoma 3Mycosis Fungoides 3

Interventions

Cisplatin 32Gemcitabine 21Radiotherapy, Intensity-Modulated 16toripalimab 14Capecitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiotherapy 7Drug Therapy 7pembrolizumab 6Platinum 6Nivolumab 6Immune Checkpoint Inhibitors 61,2-diaminocyclohexaneplatinum II citrate 6Docetaxel 5tislelizumab 4spartalizumab 4camrelizumab 4sintilimab 3anlotinib 3Immunoglobulin G 3Disulfides 3Carboplatin 3nimotuzumab 2fludarabine 2atezolizumab 2Taxes 2Radiation 2Phantoms, Imaging 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × cemiplimab × 1 year × Clear all
NCT06980038 2026-06-01

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡